The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...
The global orphan drug market size was USD 154.20 Billion in 2022 and is expected to register a rapid revenue CAGR of 12.3 % ...
The European orphan drug market is growing and is already comparable in size and scope to the US market. The European Union ...
With orphan drugs typically being high value, the potential risk of stock losses should be a top concern for biotechs looking ...
The FDA granted orphan drug status to rhenium-186 obisbemeda for treating leptomeningeal metastases in lung cancer.
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...
ENCell’s investigational drug EN001 has been granted Orphan Drug Designation by the FDA for the treatment of ...
Plus Therapeutics (PSTV) soars with FDA's Orphan Drug Designation for Rhenium Obisbemeda, targeting rare leptomeningeal metastases.
The investigational immunotherapy bexmarilimab has been granted orphan drug designation from the FDA for patients with ...
Tucatinib inhibits the tyrosine kinase enzyme of the HER-2 gene. Mutations of tyrosine kinase in the HER-2 gene lead to ...
Detailed price information for Diagnamed Holdings Corp. (DMED-CN) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results